title: CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma.
abstract: Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma. CIP2A has recently been described as a prognostic marker in many cancers. In this study, we assessed the value of this novel prognostic marker in PTC. A total of 178 surgical specimens of both benign and malignant thyroid tumors were collected. Immunohistochemical staining for CIP2A, HBME-1, galectin-3, and CK19 was performed. Western blotting for CIP2A was also performed. CIP2A was expressed in 85.3% of malignant tumors and 12.1% of benign tumors. ROC analysis showed that the AUC for CIP2A was higher than those for other tumor markers. Western blotting showed that CIP2A expression was higher in PTC than in other tumors. Poor progression-free survival was observed in the high-CIP2A expression group. High CIP2A expression is a poor prognostic factor and can be a diagnostic marker in PTC. The presence of any two of the three indicated makers (CIP2A, galectin-3, and HBME-1) is strongly correlated with the diagnosis of PTC.
authors.affiliation: Medical Research Center, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Ting-Ting
authors.initials: TT
authors.lastname: Chao
authors.affiliation: Department of Pathology, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Hung-Chune
authors.initials: HC
authors.lastname: Maa
authors.affiliation: Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Cheng-Yi
authors.initials: CY
authors.lastname: Wang
authors.affiliation: Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Dee
authors.initials: D
authors.lastname: Pei
authors.affiliation: Department and Institute of Life-Science, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.|Graduate Institute of Applied Science and Engineering, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Yao-Jen
authors.initials: YJ
authors.lastname: Liang
authors.affiliation: Department and Institute of Life-Science, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.|Graduate Institute of Applied Science and Engineering, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Yi-Feng
authors.initials: YF
authors.lastname: Yang
authors.affiliation: Department of Surgery, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Shuo-Jiun
authors.initials: SJ
authors.lastname: Chou
authors.affiliation: Department of Pathology, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
authors.forename: Yen-Lin
authors.initials: YL
authors.lastname: Chen
mesh_terms: D000328:Adult; D001324:Autoantigens / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D002277:Carcinoma / Q000175:diagnosis* / Q000473:pathology*; D002291:Carcinoma, Papillary; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008565:Membrane Proteins / Q000032:analysis*; D008875:Middle Aged; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D016019:Survival Analysis; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000473:pathology*
chemical_list: D001324:Autoantigens; D014408:Biomarkers, Tumor; C500266:CIP2A protein, human; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins
keywords: CIP2A; Thyroid; diagnosis; papillary carcinoma; prognosis